Biogen’s Plegridy (peginterferon beta-1a) and Avonex (interferon beta-1a) Receive CHMP’s Positive Opinion to Use During Pregnancy and Breastfeeding

Shots:

• The CHMP recommended an update to MAA of approved interferon beta treatments (Plegridy & Avonex) to remove pregnancy contraindications and allow them to use during pregnancy and breastfeeding in women with relapsing multiple sclerosis
• The CHMP positive opinion is based on 1,000+ real-world pregnancy outcomes demonstrating no increased risk of major congenital anomalies after exposure to interferon beta before conception and/or during the first trimester
• Plegridy (q2w) is subcutaneous pegylated interferon indicated in RRMS while AVONEX is one of the most prescribed treatments for relapsing forms of MS, currently approved in 90+ countries

Click here to­ read full press release/ article | Ref: Biogen | Image: The Business Journal